ERBB2 and breast carcinoma: The machine learning algorithm was trained, tested, and validated using data from patients with cT1-3, cN0 or +, HER-2+, triple-negative, or high-proliferative luminal B-like breast cancer who underwent VAB prior to standard breast surgery.